NEJM Audio Summary - Sep 22, 2011

TIME TABLE

00:53 | Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
02:41 | Resolving the Scar of Pulmonary Fibrosis
03:16 | Lebrikizumab Treatment in Adults with Asthma
04:37 | Asthma Phenotypes and Interleukin-13 — Moving Closer to Personalized Medicine
05:18 | Long Interdialytic Interval and Mortality among Patients Receiving Hemodialysis
06:47 | Rotavirus Vaccine and Health Care Utilization for Diarrhea in U.S. Children
08:28 | Current Concepts: Hepatocellular Carcinoma
10:13 | Case 29-2011 — A 66-Year-Old Woman with Cardiac and Renal Failure
11:26 | Reforming the Regulations Governing Research with Human Subjects
12:55 | Eliciting Mucosal Immunity
14:32 | Confronting Alzheimer's Disease
16:15 | The Threat of Artemisinin-Resistant Malaria
18:02 | Health Care Policy in an Age of Austerity
19:18 | Porphyria Cutanea Tarda
20:18 | Renal Tuberculosis

NEJM BLOGGERS

• 内科開業医のお勉強日記「特発性肺線維症：チロシンキナーゼ阻害薬 BIBF 1120の有効性」
• 呼吸器内科医「特発性肺線維症に対するBIBF 1120 の有用性」
• 内科開業医のお勉強日記「抗ＩＬ１３治療：Lebrikizumabによるコントロール不良喘息治療 periostin値による層別化有効」
• 呼吸器内科医「ステロイド抵抗性喘息にlebrikizumabは有用」

EXCERPTED SCRIPT

"The Threat of Artemisinin-Resistant Malaria", a PERSPECTIVE article by Arjen Dondorp, from Mahidol University, Bangkok, Thailand
Since the 1970's when Chinese researchers demonstrated the artemisinins antimalarial potency, artesiminin based combination therapy has become key to malaria control. But reduced susceptibility of Plasmodium falciparum to artemisinin derivatives has been documented in the Cambodia–Thailand border region.  Although most P. falciparum infections still eventually clear after treatment with artemisinin-based combination therapies, resistant parasites take 3 or 4 days to do so, as compared with less than 2 days for artemisinin-sensitive parasites. This delayed clearance could be a step toward high-level resistance and frank treatment failure. Since the artemisinins have very short half-lives, this loss of potency also renders the more slowly eliminated drugs that are part of combination therapies vulnerable to development of resistance. The gravity of this threat has been recognized, and an ambitious program to contain artemisinin resistance has been launched under the guidance of the World Health Organization. Still, several critically important questions about artemisinin resistance and containment merit urgent attention. The artemisinins have been crucial to recent successes in reducing the malaria burden, and artemisinin-based combination therapies are essential to all plans for malaria elimination. Losing artemisinins to resistance will not only jeopardize the goal of malaria eradication, but will also result in large increases in African childhood mortality.

今年はLasker-DeBakey臨床医学研究賞を上記中国研究者の筆頭である屠呦呦(Tu Youyou)女史が受賞されたのですね。